Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19
Status:
Recruiting
Trial end date:
2022-09-15
Target enrollment:
Participant gender:
Summary
To determine if the reduction in TMPRSS2 activity via direct inhibition with Camostat
mesilate combined with standard of care (SOC) treatment will increase the proportion of
patients alive and free from respiratory failure at Day 28 in SARS-CoV-2 as compared to SOC
treatment with placebo.